Sign Out
Treatment of infections caused by ≥1 susceptible organisms including lower respiratory tract infections eg, acute and chronic bronchitis and pneumonia, and upper respiratory tract infections eg, sinusitus and pharyngitis.
Initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens (see Pharmacology: Microbiology under Actions).
Skin and soft tissue infections of mild to moderate severity.
For the eradication of Helicobacter pylori in patients with proven duodenal ulcers, in the presence of acid suppression effected by omeprazole.
